Sun Pharma Settles Litigation With Novartis

Stricter Scrutiny For Indian Pharma Exports
  • Sun Pharmaceuticals has entered into a settlement with Novartis Pharmaceuticals to dismiss the lawsuit filed against it in regard to the launch of the generic version of Novartis’s Gleevec (used to treat chronic myeloid leukemia).
  • Tentative approval subject to customary approvals has been granted to Sun Pharma’s subsidiary by the Food and Drug Administration (FDA) to launch its generic version in US.
  • $82 million sales for a two-month period has been factored for Gleevec based on 30 %  price erosion and a 35 % market share for a two-month period.